ReviewMedicine2026
Relationship between breast cancer and metformin: A bibliometric review.
Review in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundA complex relationship exists between diabetes, particularly type 2 diabetes, and breast cancer. Metformin can help reduce the incidence of cancer and the risk of death in individuals with type 2 diabetes. This study utilized bibliometrics to analyze the potential impact of diabetes drugs on the treatment of breast cancer, aiming to reveal research trends and provide references for future research directions.
methodsThis bibliometric study analyzed the intersection of diabetes, breast cancer, and metformin using data from the Web of Science Core Collection and PubMed (2004-2024). A total of 1080 relevant publications were included.
resultsAn initial slow growth in publications was noted, followed by a surge starting in 2008. The USA and China led these research efforts, with Goodwin PJ having the highest number of publications. The journal Diabetes Care was the most co-cited, with keywords such as "breast cancer," "risk," "metformin," and "growth" frequently appearing. The analysis identified 4036 institutions and 5214 active authors in the field.
conclusionsDespite growing attention to the role of diabetes medications such as metformin in breast cancer treatment, research remains limited to mechanistic studies and retrospective clinical analyses. The optimal dose for clinical use remains unclear, which highlights the need for further experimental studies. This study provides valuable insights for both academic and clinical research, supporting the potential use of metformin to manage the relationship between diabetes and breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.